Veraxa Biotech AG rose 15.3% on Thursday, October 29, 2026, on 363,000 shares. No headline about VRXA came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
Veraxa Biotech AG (VRXA:NASDAQ) closed at $1.02 on November 3, 2026, down 0.97% on the day. The stock trades 96.3% below its 52-week high of $27.36 and 7.4% above its 52-week low of $0.950. Over the past year, it lost 90.3%. Veraxa Biotech AG is part of the Health Care sector.
In 221 trading sessions since December 16, 2025, VRXA closed higher on 77 days (35%). Its best day was June 11, 2026 (+44.84%) and its worst was June 16, 2026 (-55.50%). The stock moved 10% or more in a single session 33 times. It opened at least 5% above the previous day's high 3 times.
At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific ADCs, bispecific T cell engagers and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research and cutting-edge technology.
Find more stocks like VRXA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.